Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer

Exclusion Criteria

• •Uncontrolled brain metastasis. Patients with known brain metastasis must have completed treatment with surgery, radiation or both. In addition, they must be off corticosteroids.
• •Symptomatic neuropathy (Grade 2 or higher)
• •Prior chemotherapy for advanced non-small cell lung cancer. (Prior adjuvant, neoadjuvant, or chemoradiotherapy for NSCLC is permitted, provided at least 6 months elapsed prior to documented metastatic recurrence.)
• •Patient is \< 5 years free of another primary malignancy, except: a) if the other malignancy is basal cell carcinoma or cervical carcinoma in situ or b) if the other primary malignancy is not considered clinically significant and is requiring no active intervention
• •Prior radiation therapy to \> 25% of bone marrow
• •Grade III/IV congestive heart failure, as defined by NYHA criteria, or myocardial infarction within 6 months.
• •Any serious or uncontrolled concomitant disorder that, in the opinion of the investigator, would compromise the patient's ability to complete the study.
• •Patient has known chronic liver disease, e.g. diagnosis of chronic active hepatitis or cirrhosis.
• •Major surgery two weeks prior to study treatment
• •Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent
• •Any condition requiring continuous administration of systemic corticosteroids.
• •The patient is on therapeutic anti-coagulation with warfarin.